All In Biotech

Drug Trial Radar · NCT05437510

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

A Phase IIIb Randomized Open-label Study of Nirsevimab (Versus no Intervention) in Preventing Hospitalizations Due to Respiratory Syncytial Virus in Infants (HARMONIE)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,057 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,057

Actual

Start

Aug 8, 2022

Primary completion

Mar 27, 2024

Study completion Apr 9, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jun 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 12 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who were not eligible to receive palivizumab. The visit frequency was 1 in-person dosing/randomization visit, with monthly safety follow-up electronic contacts through the first 6 months post dosing/randomization for all participants. The study also included a 12-month (Day 366) follow-up telephone call. The D366 follow-up telephone call was the final follow-up telephone call for France, Germany and UK non-reconsented participants. The study included an 18-month (D546) and a 24-month (D731, final telephone call) follow-up telephone call for UK reconsented participants.

Conditions

  • RSV Immunization
  • Healthy Volunteer

Interventions

  • NirsevimabBiological

    Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus SeasonTime frame: From dosing/randomization (Day 1) up to approximately 7 months

Locations

240 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigational Site 2500041

    Aix-en-Provence, France

  • Investigational Site 2500002

    Amiens, France

  • Investigational Site Number: 2500014

    Bordeaux, France

  • Investigational Site 2500007

    Brest, France

  • Investigational Site Number: 2500038

    Brest, France

  • Investigational Site Number: 2500045

    Brest, France

  • Investigational Site Number: 2500019

    Bron, France

  • Investigational Site Number: 2500043

    Brumath, France

  • Investigational Site Number: 2500001

    Caen, France

  • Investigational Site Number: 2500032

    Chambéry, France

  • Investigational Site Number: 2500057

    Clamart, France

  • Investigational Site Number: 2500065

    Clamart, France

  • Investigational Site Number: 2500029

    Combs-la-Ville, France

  • Investigational Site Number: 2500013

    Corbeil-Essonnes, France

  • Investigational Site Number: 2500054

    Creil, France

  • Investigational Site Number: 2500006

    Créteil, France

  • Investigational Site Number: 2500039

    Créteil, France

  • Investigational Site Number: 2500023

    Dijon, France

  • Investigational Site Number: 2500069

    Draguignan, France

  • Investigational Site 2500008

    Essey-lès-Nancy, France

  • Investigational Site 2500030

    Étampes, France

  • Investigational Site Number: 2500058

    Frouard, France

  • Investigational Site Number: 2500064

    Grasse, France

  • Investigational Site Number: 2500004

    Grenoble, France

  • Investigational Site Number: 2500027

    Héry-sur-Alby, France

  • Investigational Site Number: 2500060

    Huningue, France

  • Investigational Site 2500059

    La Garenne-Colombes, France

  • Investigational Site Number: 2500071

    La Teste-de-Buch, France

  • Investigational Site Number: 2500034

    Le Kremlin-Bicêtre, France

  • Investigational Site Number: 2500072

    Libourne, France

  • Investigational Site 2500046

    Lille, France

  • Investigational Site 2500005

    Lille, France

  • Investigational Site Number: 2500012

    Limoges, France

  • Investigational Site Number: 2500037

    Longjumeau, France

  • Investigational Site 2500021

    Maromme, France

  • Investigational Site Number: 2500003

    Marseille, France

  • Investigational Site Number: 2500073

    Marseille, France

  • Investigational Site Number: 2500068

    Mont-de-Marsan, France

  • Investigational Site Number: 2500066

    Mont-Saint-Aignan, France

  • Investigational Site Number: 2500067

    Montpellier, France

Showing 40 of 240 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.